STAT+: Amgen, Arrakis Therapeutics partner to develop oral drugs that eliminate troublesome RNA

Amgen and the biotech startup Arrakis Therapeutics announced a research collaboration to discover and develop a new class of oral drugs that selectively destroy troublesome RNA molecules.

Click to view original post